Latest Insider Transactions at Dyne Therapeutics, Inc. (DYN)
This section provides a real-time view of insider transactions for Dyne Therapeutics, Inc. (DYN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dyne Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dyne Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,635
-1.5%
|
$16,350
$10.41 P/Share
|
|
Sep 12
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,266
-2.01%
|
$12,660
$10.41 P/Share
|
|
Sep 12
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,397
-3.21%
|
$13,970
$10.41 P/Share
|
|
Jun 15
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
10,000
-18.7%
|
$120,000
$12.03 P/Share
|
|
Jun 13
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
41,390
-22.66%
|
$496,680
$12.66 P/Share
|
|
Jun 13
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+29.97%
|
$40,000
$1.03 P/Share
|
|
Jun 13
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,698
-1.83%
|
$20,376
$12.43 P/Share
|
|
Jun 13
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,625
-1.47%
|
$19,500
$12.43 P/Share
|
|
Jun 13
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,259
-1.96%
|
$15,108
$12.43 P/Share
|
|
Jun 13
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,475
-1.66%
|
$17,700
$12.43 P/Share
|
|
Jun 12
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.53%
|
$13,000
$13.0 P/Share
|
|
Jun 12
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
187,748
-42.56%
|
$2,252,976
$12.61 P/Share
|
|
Jun 12
2023
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
171,360
+27.98%
|
$171,360
$1.03 P/Share
|
|
Jun 09
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
76,582
-22.11%
|
$995,566
$13.34 P/Share
|
|
Jun 09
2023
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
76,582
+18.11%
|
$76,582
$1.03 P/Share
|
|
Jun 08
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
61,000
-9.57%
|
$793,000
$13.31 P/Share
|
|
Jun 08
2023
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,088
+8.34%
|
$30,088
$1.03 P/Share
|
|
Jun 08
2023
|
Joshua T Brumm CEO & President |
SELL
Bona fide gift
|
Direct |
21,800
-3.4%
|
-
|
|
Mar 14
2023
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,559
-1.39%
|
$20,267
$13.33 P/Share
|
|
Mar 14
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,209
-1.82%
|
$15,717
$13.33 P/Share
|
|
Mar 14
2023
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,311
-2.33%
|
$17,043
$13.33 P/Share
|
|
Mar 14
2023
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,416
-1.57%
|
$18,408
$13.33 P/Share
|
|
Mar 14
2023
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
7,318
-2.22%
|
$95,134
$13.33 P/Share
|
|
Mar 14
2023
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,441
-7.43%
|
$96,733
$13.33 P/Share
|
|
Mar 13
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.48%
|
$13,000
$13.0 P/Share
|
|
Jan 18
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.89%
|
$140,000
$14.03 P/Share
|
|
Jan 18
2023
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.42%
|
$0
$0.73 P/Share
|
|
Jan 09
2023
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
30,150
-30.84%
|
$331,650
$11.57 P/Share
|
|
Dec 12
2022
|
Atlas Venture Opportunity Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
934,581
+50.0%
|
$9,345,810
$10.7 P/Share
|
|
Dec 12
2022
|
Jason P Rhodes |
BUY
Open market or private purchase
|
Indirect |
934,581
+50.0%
|
$9,345,810
$10.7 P/Share
|
|
Dec 12
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
680
-0.75%
|
$6,800
$10.87 P/Share
|
|
Dec 12
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
3,322
-1.0%
|
$33,220
$10.87 P/Share
|
|
Dec 12
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
628
-0.62%
|
$6,280
$10.87 P/Share
|
|
Dec 12
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
751
-0.67%
|
$7,510
$10.87 P/Share
|
|
Dec 12
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
472
-0.48%
|
$4,720
$10.87 P/Share
|
|
Dec 12
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
312
-0.55%
|
$3,120
$10.87 P/Share
|
|
Dec 09
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+30.58%
|
-
|
|
Dec 09
2022
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
144,000
+30.18%
|
-
|
|
Dec 09
2022
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+26.33%
|
-
|
|
Dec 09
2022
|
Susanna Gatti High Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+28.06%
|
-
|
|
Dec 09
2022
|
Jonathan Mc Neill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+28.94%
|
-
|
|
Dec 09
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+35.43%
|
-
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
SELL
Bona fide gift
|
Direct |
15,500
-3.83%
|
-
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
195,800
-48.9%
|
$2,349,600
$12.46 P/Share
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
195,800
+32.84%
|
$195,800
$1.03 P/Share
|
|
Oct 07
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
14,200
-6.49%
|
$184,600
$13.37 P/Share
|
|
Oct 07
2022
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,200
+6.09%
|
$14,200
$1.03 P/Share
|
|
Sep 20
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
840
-3.19%
|
$10,920
$13.7 P/Share
|
|
Sep 20
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,246
-2.1%
|
$16,198
$13.7 P/Share
|
|
Sep 20
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,629
-3.68%
|
$34,177
$13.7 P/Share
|